

# Mastic Gum and Helicobacter Pylori eradication: an in vivo pilot study

<b>Submission date</b> 31/03/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 29/04/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 20/09/2010	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English Summary

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Konstantinos Dabos

### Contact details

Helenas Venizelou 2  
Chios  
Greece  
821-00  
kostasophia@yahoo.com

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

MGHP05

## Study information

Scientific Title

**Acronym**

MGHP

**Study hypothesis**

Mastic gum is effective in eradicating *Helicobacter pylori* in vivo.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics approval received from the Greek Medicines Agency Ethics Board on the 18th December 2005 (ref: MGCGH0032/06).

**Study design**

Randomised controlled trial with three arms

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet****Condition**

*Helicobacter pylori* gastritis

**Interventions**

Patients positive to *Helicobacter pylori* will be randomised to receive one of the following:

1. Mastic gum 2 g per day for 14 days
2. Mastic gum 2 g per day and pantoprazole 40 mg per day for 14 days
3. Pantoprazole 40 mg per day, amoxicillin 2 g per day and clarithromycin 1 g per day for 10 days

Follow up was two months after the end of the treatment for all study arms.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Mastic gum, pantoprazole, amoxicillin, clarithromycin

### **Primary outcome measure**

Eradication of Helicobacter pylori, measured at five weeks after the end of treatment.

### **Secondary outcome measures**

Helicobacter pylori load in patients remaining H. pylori positive, measured at five weeks after the end of treatment.

### **Overall study start date**

01/12/2006

### **Overall study end date**

01/06/2007

## **Eligibility**

### **Participant inclusion criteria**

1. Patients tested positive for H. pylori
2. Adults of either sex aged between 18 and 75 years of age

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Lower age limit**

18 Years

### **Upper age limit**

75 Years

### **Sex**

Both

### **Target number of participants**

42

### **Participant exclusion criteria**

1. Pregnancy
2. Malignancy
3. Allergies to pantoprazole, amoxicillin, clarithromycin

### **Recruitment start date**

01/12/2006

### **Recruitment end date**

01/06/2007

# Locations

## Countries of recruitment

Greece

## Study participating centre

**Helenas Venizelou 2**

Chios

Greece

821-00

# Sponsor information

## Organisation

The Chios Mastic Gum Producers Cooperative (Greece)

## Sponsor details

Konstantinou Monomahou 1

Chios

Greece

821-00

## Sponsor type

Industry

## Website

<http://www.gummastic.gr>

## ROR

<https://ror.org/05rpby975>

# Funder(s)

## Funder type

Industry

## Funder Name

The Chios Mastic Gum Producers Cooperative (Greece)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/03/2010		Yes	No